ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the designation as an Orphan drug of its pan-HER inhibitor varlitinib (ASLAN001) by the Korean Ministry of Food and Drug Safety (MFDS), for the treatment of advanced biliary tract cancer after first line systemic therapy.

This is the third Orphan Drug Designation for varlitinib which has previously received orphan status for cholangiocarcinoma and gastric cancer from the United States Food and Drug Administration (FDA).

The MFDS awards Orphan Drug Designation to advance the development of drugs targeted for treating rare diseases that do not have any available treatments in Korea.

For more information, please refer to the English or Chinese press release.